CVR 44512971Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)Secondary industries: Fremstilling af farmaceutiske råvarer (211000)København NFounded 19 Dec 2023
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Gefjon Pharma ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
6
CVR, Aug 2026
0 (0%) over 12 months
Gross profit
-2.2M
DKK, annual report 2026
Result
-4.2M
DKK, annual report 2026
Equity
-5M
DKK, annual report 2026
Copenhagen Equity ApSCVR 42119539, 20% to under 25% of capital and votes
North2k ApSCVR 44344742, 20% to under 25% of capital and votes
and 2 moreOperating company
Dandex estimate: 6 employees registered in 2026Thomas Frees Buthlersince 19 Dec 2023
Anders Miki Bojesensince 27 Jan 2025
Torben Haldsince 1 Sep 2024
and 1 moreOwners of 5% or more. CVR registers shares in bands, not exact figures. All notified 16 Nov 2026.
CVR 4211953920% to under 25% of capital and votessince 19 Dec 2023
CVR 4434474220% to under 25% of capital and votessince 19 Dec 2023
CVR 4437057320% to under 25% of capital and votessince 19 Dec 2023
20% to under 25% of capital and votessince 19 Dec 2023
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Founded 19 Dec 2023.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 6 employees, 4 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 2 | 5 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 6 | 6 |
| FTE | 0 | 1 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 3 | 4 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2026, DKK: Gross profit -2.2M, Operating profit -4.4M, Result for the year -4.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2026, DKK: Total assets 7.9M, Equity -5M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2025 | 2026 |
|---|---|---|
| Gross profit | 470 | -2,230 |
| Operating profit | -248 | -4,402 |
| Result for the year | -196 | -4,245 |
| Equity | -156 | -4,998 |
| Total assets | 5,331 | 7,868 |
| Employees (average) | 0 | 5 |
| Credit metrics (Dandex calculations) | ||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | |
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |
Not every period is a full year: 2025 covers 15 months (19 Dec 2023 to 31 Mar 2025). Changes against it compare periods of different length.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Gefjon Pharma ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 3,000,000, cash price 2,204.26, implied value 91,170,464 | 2,204.26 | 3,000,000 | 91,170,464 | 41,361 | |
| FoundingCashPaid in 40,000 | None | 40,000 | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
8 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Vedtægter ændret: 16.11.2026
Kapitalforhøjelsen er besluttet den 16.11.2026.
kr. 1.361,00, indbetalt kontant, kurs 220.426,16.
Kapitalen udgør herefter kr. 41.361,00.
Vedtægter ændret: 10.06.2026
Revision:
Tiltrådte:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Strandvejen 44, 2900 Hellerup, den 10.06.2026.
Vedtægter ændret: 03.02.2026
Bestyrelse:
Tiltrådte:
Fabio Antenucci, den 03.02.2026, Anders Miki Bojesen, (formand), den 03.02.2026, Thomas Frees Buthler, den 03.02.2026, CEO Torben Hald, den 03.02.2026.
Selskabet tegnes af 2 direktører i forening eller af den samlede bestyrelse.
Ny adresse: c/o Torben Hald, Ole Maaløes Vej 3, 2200 København N
Ny kommune: København
Direktion:
Tiltrådte:
Fabio Antenucci, den 27.01.2025, Anders Miki Bojesen, den 27.01.2025, Thomas Frees Buthler, den 27.01.2025.
Vedtægter ændret: 10.10.2024
Første regnskabsår: 19.12.2023 - 31.03.2025
Regnskabsår ændret til: 01.04 - 31.03
Ny adresse: c/o Torben Hald, Thorvaldsensvej 57, 1871 Frederiksberg C
Ny kommune: Frederiksberg
Direktion:
Fratrådte:
Thomas Frees Buthler, den 23.09.2024.
Tiltrådte:
Torben Hald, (adm. dir), den 01.09.2024.
Stiftelsesdato: 19.12.2023.
Virkningsdato: 19.12.2023.
Seneste vedtægtsdato: 19.12.2023.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
HAVITO AS, Melingsiden 34D, 4056 Tananger, Norge, den 19.12.2023, CVR-NR. 42119539 Copenhagen Equity ApS, c/o Anders Miki Bojesen, Strandboulevarden 23, st. th, 2100 København Ø, den 19.12.2023, CVR-NR. 44344742 North2k ApS, Isefjords Alle 19, 3. th, 4300 Holbæk, den 19.12.2023, CVR-NR. 44370573 TBU Holding 2023 ApS, c/o Thomas Buthler, Engelstedsgade 27, st., 2100 København Ø, den 19.12.2023.
Direktion:
Thomas Frees Buthler, den 19.12.2023.
Selskabet tegnes af en direktør.
Første regnskabsår:
19.12.2023 - 31.12.2024.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive virksomhed med udvikling, produktion og salg af lægemidler til levnedsmiddelindustrien samt enhver anden aktivitet, som efter ledelsens skøn står i forbindelse hermed.
P-number 1029939361Ole Maaløes Vej 3, 2200 København N
No other current company drawn.